NasdaqGS:NTRABiotechs
Does Natera’s (NTRA) Expanded Genomics Suite Quietly Redefine Its Long-Term Competitive Moat?
Natera recently reported peer-reviewed data underscoring the clinical utility of its Signatera ctDNA assay in anal squamous cell carcinoma and locally advanced rectal cancer, while also launching Zenith genomics, a next-generation whole genome sequencing test for rare disease diagnosis in partnership with MyOme.
Together, these developments highlight Natera’s push to link stronger clinical evidence with broader genomic offerings, potentially influencing how clinicians balance cancer...